Carol was 57 when her first DEXA scan came back showing osteoporosis of the lumbar spine and osteopenia at the hip. She was floored. She’d been active her whole life, never broken a bone, ate dairy regularly — all the things you’re supposed to do. Her gynecologist prescribed alendronate, a bisphosphonate. Carol had questions. How bad was this, really? Would the medication actually help? And why hadn’t anyone told her to start protecting her bone density at 40 instead of finding out at 57 that she’d already lost a meaningful chunk of it? That last question has the same answer it always has in preventive medicine: because the default healthcare approach waits for the condition to show up before addressing it, rather than building the resilience that would have kept it from showing up at all.
Bone Is Not Static: A Living Tissue in Constant Flux
Bone is not inert mineral sitting there doing nothing. It’s a dynamic, living tissue in constant remodeling. Osteoclasts continuously resorb old bone, dissolving the mineralized matrix; osteoblasts then lay down new matrix, which subsequently mineralizes. This cycle is how the skeleton maintains structural integrity, repairs the microdamage of daily stress, and regulates calcium for the body’s physiological needs. In young adults, formation and resorption stay balanced — net bone mass holds steady. Peak bone mass arrives in the late 20s to early 30s.
The female bone density trajectory has two critical turning points. First, peak bone mass, around 25-30 years: density at its lifetime maximum. Whatever capital got accumulated by this point is the baseline every future loss gets subtracted from. Second, menopause: estrogen — the primary hormonal brake on osteoclast activity — drops precipitously. Without that restraint, osteoclast activity accelerates hard. The first 5-7 years after menopause can see bone density losses of 2-3% per year, versus the 0.5-1% typical of premenopausal aging. This accelerated window is the main driver of osteoporosis in women. Not a footnote. The main driver.
The fracture sites that matter clinically are the hip (femoral neck and trochanter), the vertebrae, and the distal radius — the classic Colles’ fracture from a fall on an outstretched hand. Hip fractures carry the worst morbidity by a wide margin: roughly 20-30% of women who fracture a hip die within a year from complications — pneumonia, pulmonary embolism, the cascading consequences of prolonged immobility. About half of survivors need long-term care or never make it back to independent living. That’s the functional endpoint all this bone density work is ultimately trying to prevent.
Building Peak Bone Mass: The Window Most Women Miss
The window for maximizing bone capital — the account every future withdrawal gets drawn from — is the first three decades of life. Bone accumulates fast during childhood and adolescence, especially the pubertal growth spurt, when 25-30% of lifetime peak bone mass gets laid down in just 2-3 years. It keeps building more slowly into the late 20s, then plateaus. Whatever happens during that window sets the starting point for every future loss.
The biggest determinants of peak bone mass: calcium and vitamin D intake during childhood and adolescence (dietary calcium during growth directly determines how much mineral is available for the expanding matrix); impact-loading exercise in youth — running, jumping, team sports, the ground-reaction forces that stimulate osteoblast activity and widen bone cross-sectional area; adequate caloric intake and body weight (energy restriction during the growth years, whether from diet choices, disordered eating, or athletic overtraining, directly impairs peak bone accumulation); and the absence of things that derail bone development — chronic glucocorticoid use, celiac disease with malabsorption, delayed puberty.
For adult women reading this in their 30s through 50s: the peak bone mass window has closed. But the investment logic still holds. The goal now is maintaining the capital that exists, not accumulating new peak bone. Bone isn’t static after peak — it can be actively built and maintained with the right stimulus, mainly resistance training and impact exercise. Post-peak gains are modest next to what inactivity and estrogen deficiency can take away, but they’re real, and they matter clinically.
Calcium: The Most Mismanaged Nutrient in Bone Health
Calcium is the dominant mineral in bone, roughly 40% of bone mass as hydroxyapatite crystals. You need adequate calcium for bone formation and maintenance — that part’s not controversial. What’s gotten overcomplicated is everything around it: supplement industry marketing on one side, a cardiovascular-driven backlash against calcium supplementation on the other. Result: plenty of women either over-supplement or give up on calcium entirely.
Recommended daily intake for bone health is 1,000mg/day for premenopausal women, 1,200mg/day postmenopausal — total intake, food plus supplements combined. Most Americans get 700-900mg from diet alone if they eat dairy regularly. A woman eating adequate dairy (three servings daily), fortified foods, and calcium-rich plants — broccoli, bok choy, almonds, white beans, fortified plant milks — may already be meeting her requirement from food. She doesn’t need extra calcium on top of that, and she may actually be harmed by it.
The cardiovascular concern traces back to the Bolland et al. meta-analyses (2010-2011) suggesting calcium supplements — not dietary calcium — raise cardiovascular event risk. The proposed mechanism: a single large supplement dose creates a big transient spike in serum calcium, which may promote vascular calcification and arterial stiffness in a way that dietary calcium, spread across meals and absorbed gradually, doesn’t. Practical guidance follows from that: meet calcium needs from food first; supplement only the gap between diet and target; split any supplemental calcium into doses no larger than 500mg, which absorbs more efficiently than a bigger single dose; and use calcium citrate over calcium carbonate — better absorbed without food, and in anyone with reduced stomach acid.
Resistance Training as Medicine
Resistance training is the single most powerful modifiable intervention for building and maintaining bone density in adult women. Full stop. The mechanism: mechanical loading through resistance exercise stimulates osteoblast activity via piezoelectric signaling in bone cells, upregulates bone morphogenetic proteins and IGF-1 locally within bone, and increases the cortical cross-sectional area and trabecular density that determine bone strength. The LIFTMOR trial (Watson et al., 2018) — high-intensity progressive resistance training at 85% 1RM with power exercises, in postmenopausal women who already had osteoporosis — showed significant increases in lumbar spine and femoral neck bone density over 8 months, along with better functional performance and no adverse events. That’s the quality of evidence clinical recommendations should be built on.
Specificity matters here: bone adapts to the specific forces applied to it. Hip and spine density — the clinically critical sites for osteoporotic fracture — respond most to exercises that load those exact regions. Squats, deadlifts, hip hinges, weighted lunges load the hip and spine. Overhead pressing loads the thoracic spine and scapular region. Running provides axial loading to spine and hip. Swimming and cycling are excellent for cardiovascular health and apply almost no load to spine or hip — they’re not bone-building exercises, whatever else they’re good for.
The dose for bone health: at least 2-3 sessions a week, progressive load over time, compound movements at 70-85% of 1-rep max — moderate to hard effort. The specific protocol matters less than the underlying principle: progressive, heavy loading through large compound movements at the relevant skeletal sites. Any supervised resistance program built on progressive overload will improve bone density. The real question is whether intensity and specificity are actually adequate.
Vitamin D and K2: The Underappreciated Bone Partners
The optimal range for bone health appears to be 50-80 ng/mL. Getting there from baseline deficiency — below 20 ng/mL, which hits over 40% of US adults — usually takes 4,000-6,000 IU per day for several months, then 2,000-3,000 IU/day to maintain. Testing serum 25-OH vitamin D before and after 3-6 months of supplementation is the evidence-based way to confirm you’ve hit target, because a universal dosing recommendation doesn’t actually work — individual response varies substantially with weight, gut absorption, baseline level, and vitamin D receptor genetics.
Vitamin K2 — menaquinone, specifically the MK-7 form — plays a distinct role from D and calcium. It activates osteocalcin, a calcium-binding protein osteoblasts produce, and matrix Gla protein, which inhibits vascular calcification. Without adequate K2, osteocalcin stays in its inactive form and can’t efficiently bind calcium into the bone matrix. K2 essentially directs calcium to bone and away from vascular tissue. Supplementing 100-200mcg MK-7 daily — the most bioavailable form, found naturally in natto and made synthetically otherwise — consistently improves markers of osteocalcin activation and has shown benefits for bone density and fracture rates in randomized trials.
The BONE Protocol: A Comprehensive Framework
Building and maintaining bone density across a woman’s lifespan means addressing hormonal environment, mechanical loading, nutritional sufficiency, and the factors that accelerate loss — all at once, not one at a time. The BONE Protocol (Build with resistance training, Optimize hormones, Nutrition foundation, Eliminate resorption drivers) structures that.
B — Build with resistance training: progressive resistance training 2-3x/week — squats, deadlifts, hip hinges, pressing movements, loaded at 70-85% 1RM. Add impact exercise (jumping, running) if it’s tolerated and medically appropriate. This is the foundation nothing else can substitute for — mechanical loading is the only direct stimulator of osteoblast activity available to you.
O — Optimize hormones: estrogen is the dominant hormonal protective factor for bone. In perimenopause and menopause, hormone replacement therapy — estrogen with or without progesterone, depending on uterine status — maintains bone density; the Women’s Health Initiative confirmed HRT prevents osteoporosis and fractures in postmenopausal women. The decision to use HRT involves an individual cardiovascular and cancer risk conversation, but bone protection is a real, genuine benefit within that calculus. Beyond that: optimize thyroid function (both hypo- and hyperthyroidism impair bone), assess vitamin D as a bone hormone rather than an afterthought vitamin, and manage diabetes if present, since type 2 diabetes independently raises fracture risk even with a normal-looking DEXA.
N — Nutrition foundation: calcium 1,000-1,200mg/day total, food first, supplement only the gap; vitamin D at 50-80 ng/mL; vitamin K2 at 100-200mcg MK-7 daily; adequate protein, since protein builds the collagen matrix framework calcium actually mineralizes into — 1.2-1.6g/kg body weight daily; magnesium as a cofactor in mineralization and vitamin D activation, 320-420mg/day.
E — Eliminate resorption drivers: chronic glucocorticoid use, including high-dose inhaled corticosteroids, is the single most potent pharmaceutical cause of bone loss — if it’s unavoidable, bone-protective medication should be co-prescribed proactively, not added later. Heavy alcohol use (over 3 drinks/day) suppresses osteoblast activity and impairs calcium absorption. Smoking independently lowers bone density and raises fracture risk through effects on osteoblasts and estrogen metabolism. Excessive thyroid hormone replacement — TSH suppression — accelerates resorption. A sedentary lifestyle removes the mechanical loading stimulus altogether.
Common Questions About Bone Health
- At what age should women get their first DEXA scan? Guidelines recommend screening for all women at 65, earlier for younger postmenopausal women with risk factors — early menopause before 45, long-term glucocorticoid use, a prior low-trauma fracture, strong family history, low body weight. Women with specific risk factors — eating disorders, celiac disease, long-term glucocorticoid use — may warrant a DEXA in their 30s or 40s. Screening earlier than that without risk factors doesn’t improve outcomes. It just increases unnecessary treatment.
- Are bisphosphonates the right treatment for all osteoporosis? They’re first-line for osteoporosis with appropriate indication — T-score below -2.5, or below -2.0 with additional risk factors, or a prior low-trauma fracture. They cut fracture risk by 40-50%. Side effects include esophageal irritation (mitigated by taking with a full glass of water and staying upright for 30 minutes) and rare long-term risks — atypical femur fractures after more than 5 years, osteonecrosis of the jaw with dental procedures. Most experts recommend a drug holiday after 5 years in lower-risk women. They’re appropriate treatment. But concurrent lifestyle work — resistance training, nutrition — is a necessary complement, not an optional add-on.
- Does dairy actually build bone? Dietary calcium from dairy contributes effectively to total calcium intake, which supports mineralization. The epidemiological case for dairy specifically preventing fractures is murkier than the dairy industry’s marketing suggests — populations with low dairy intake can have perfectly adequate bone density from other calcium sources. What matters is adequate total calcium from any source, combined with vitamin D for absorption and mechanical loading for the remodeling stimulus.
- Can you reverse osteoporosis with exercise alone? Exercise can modestly improve bone density even with established osteoporosis, but the magnitude — typically 1-3% over 12 months — isn’t enough to pull a T-score back out of the osteoporotic range. Exercise’s real value in established osteoporosis is maintaining what’s left, cutting fall risk through better balance and strength, and improving functional outcomes generally. For established osteoporosis with real fracture risk, pharmacological treatment is typically indicated alongside exercise — not swapped in for it.
- Does protein intake affect bone health? Yes — positively, despite the old myth that high protein is acidic and leaches calcium from bone. That concern traced back to early short-term metabolic studies showing more urinary calcium with high protein intake. Longer studies and meta-analyses since then consistently show higher dietary protein tracks with better bone density and lower fracture risk. Protein is needed for the collagen matrix framework of bone — collagen type I is roughly 30% of bone by weight. Adequate protein (1.2-1.6g/kg/day) belongs in any bone-supportive nutritional pattern.
Your skeleton is the infrastructure of your independence. The bone density choices you make in your 30s and 40s determine whether you fracture your hip at 75 and spend the rest of your life in a nursing home, or walk out of that same hospital on your own two feet. That’s not hyperbole — it’s statistics.
Fall Prevention: The Other Half of Fracture Prevention
A fracture is the intersection of two variables: bone strength (density, microarchitecture, bone quality) and the force applied to bone (fall mechanics, impact energy). Most osteoporotic fractures need a fall to happen — they’re not spontaneous, with the exception of vertebral compression fractures that can occur under the minor stresses of everyday activity. Reduce fall risk and you reduce fracture risk directly, independent of density.
The best-supported fall risk interventions in older women: balance training (Tai Chi has the strongest evidence base of anything for fall risk reduction — multiple RCTs show 30-40% fewer falls with consistent practice); lower extremity strength training (weak hip abductors and quadriceps are among the strongest predictors of falling — the same resistance training that builds bone also reduces falls by strengthening the muscles that stabilize balance); vision correction (uncorrected visual impairment is one of the most fixable fall risk factors — regular eye exams, prompt correction of refractive error, cataracts, and other pathology); and home modification — removing loose rugs, adding bathroom grab bars, improving stairway and nighttime lighting.
Medication review is a critical, underused piece of fall prevention. Several drug classes directly raise fall risk: sedative-hypnotics (benzodiazepines, Z-drugs like zolpidem, sedating antihistamines), opioids, first-generation antidepressants (tricyclics), certain antihypertensives that cause orthostatic hypotension, and polypharmacy — taking 5+ medications, regardless of class, independently raises fall risk through interactions and cumulative side effects. A systematic review by a pharmacist or geriatrician in older women with a fall history should identify and, where possible, reduce the medications contributing to that risk.
Hip protectors — padded garments over the greater trochanter — absorb impact energy from lateral falls and can cut hip fracture risk 50-60% in institutional settings. They’re less effective for community-dwelling older adults, mainly because adherence is hard — a hip protector only works if it’s on during the fall that actually happens. For women with very high fracture risk who are genuinely willing to wear them consistently, they’re a worthwhile adjunct.
Pharmacological Treatment Options: Beyond Bisphosphonates
When pharmacological treatment is indicated — a FRAX 10-year major osteoporotic fracture risk above 20%, or T-score below -2.5, or a prior low-trauma fracture — which medication makes sense depends on fracture risk magnitude, patient characteristics, and preference. Understanding the options is what makes informed shared decision-making actually possible.
Bisphosphonates (alendronate, risedronate, zoledronic acid) inhibit osteoclast activity, reducing resorption. They accumulate in bone and keep working for years after you stop. Weekly oral alendronate or risedronate are the most common; annual IV zoledronic acid is the most convenient option and has the strongest evidence for preventing hip fracture specifically. The “drug holiday” concept — stopping after 5 years in lower-risk women — exists because of the rising risk of atypical femoral fractures with prolonged use. Higher-risk women (T-score below -3, prior fracture) should stay on treatment longer, with ongoing reassessment.
Denosumab (Prolia, Xgeva) is a monoclonal antibody against RANK-L, the signal that activates osteoclasts. Given as a subcutaneous injection every 6 months, it’s more convenient than weekly oral bisphosphonates and works for women who can’t tolerate them or who have kidney disease, since bisphosphonates need adequate renal function. Here’s the critical caveat: stopping denosumab without transitioning to a bisphosphonate causes rapid bone density loss — rebound resorption, with increased vertebral fracture risk within 12 months of stopping. Denosumab needs a clear transition plan built in before you start.
Anabolic agents — teriparatide (Forteo), abaloparatide (Tymlos), romosozumab (Evenity) — actually build new bone rather than just slowing resorption. They’re reserved for the highest-risk women: severe osteoporosis, multiple vertebral fractures, very low T-scores, where the goal is genuine bone formation, not just holding the line. They’re more expensive, require injection (daily for teriparatide/abaloparatide, monthly for romosozumab), and have duration limits. They’re followed by bisphosphonate treatment to lock in the gains. Romosozumab combines anabolic and anti-resorptive effects; it’s contraindicated in women with recent cardiovascular events because of a small observed increase in cardiovascular risk in trials.
Collagen and Bone Matrix Quality: Beyond Mineral Density
DEXA captures the mineral content of bone but doesn’t fully capture bone quality — the structural properties determining how bone actually performs under stress. That depends on trabecular microarchitecture, cortical thickness, and the quality of the collagen type I matrix providing bone’s tensile strength and toughness. Bone with adequate mineral density but a poor collagen matrix fractures more easily than the T-score alone would suggest.
Collagen synthesis needs adequate protein, vitamin C, zinc, and copper as cofactors. Glycine — the dominant amino acid in type I collagen — is the major structural amino acid of bone matrix. Collagen peptide supplementation, 10-15g/day of hydrolyzed collagen, has shown modest improvements in bone quality markers across several studies, though the evidence is still developing. The logic: providing the specific amino acids in the proportions needed for collagen synthesis — heavy on glycine, proline, hydroxyproline — supports optimal matrix formation. Osteoblasts build the collagen matrix that mineralizes into bone; giving them adequate substrate supports the whole process.
Oxidative stress damages collagen through glycation — glucose attaching to collagen molecules and degrading their mechanical properties, the same process behind glycated hemoglobin A1c in diabetes. High blood glucose and advanced glycation end-products impair collagen quality in bone the same way they do everywhere else in the body. The dietary patterns that manage blood glucose — cutting refined carbs, sugar, ultra-processed food — protect collagen quality in bone right along with everything else. Another pathway where metabolic health connects directly to skeletal health.
Carol’s story after diagnosis: weekly alendronate, resistance training with a trainer who understood bone-loading specificity, vitamin D optimized from 22 to 68 ng/mL, calcium citrate to fill the gap in her diet, K2 and magnesium added. Her DEXA at 2 years showed lumbar spine T-score improving from -2.8 to -2.3, femoral neck from -2.1 to -1.9 — clinically meaningful gains. More important than the numbers: she understood what she was doing and why, which meant she actually did it consistently instead of taking a pill and hoping. That combination — pharmacological treatment plus targeted lifestyle change with real understanding of the biology behind it — is what changes an osteoporosis trajectory. Not any single piece alone.
Estrogen and Bone: The Menopause Transition in Detail
The menopausal bone loss story is familiar in broad strokes, but it’s worth detailing the timeline and magnitude specifically, because that’s what clarifies both the urgency of early intervention and the limits of late intervention.
During perimenopause, typically 47-52 years for most women, as estradiol starts declining, resorption begins outpacing formation. The loss rate accelerates from the premenopausal 0.5-1% per year to roughly 2-3% per year in the first 3-7 years after the final period — the “early postmenopause” acceleration window. Over 7-10 years, that adds up to a 15-25% decrease in bone density from the premenopausal peak. Late postmenopause, beyond 7-10 years out, sees loss slow back to roughly 0.5-1% per year — similar to premenopausal aging, but from a much lower starting point.
Here’s the implication: if HRT is going to be used for bone protection, starting it early in the transition provides the most benefit, because it prevents the accelerated early-postmenopause loss in the first place. Late initiation — 10-plus years after menopause — provides less bone benefit, since the accelerated window has already passed, and it may carry higher cardiovascular risk (the “timing hypothesis” from the WHI re-analysis, which suggests HRT started within 10 years of menopause has a more favorable cardiovascular profile than late initiation). This timing dependency is part of why the HRT decision should be made proactively in perimenopause, not reactively after significant bone loss has already happened.
Women with premature ovarian insufficiency — ovarian failure before age 40 — or surgical menopause from oophorectomy before natural menopause face an extended stretch of estrogen deficiency before the natural menopausal age would have arrived. They accumulate disproportionate bone loss across that extended window. HRT is essentially standard of care for these women, at least until the natural menopausal age of roughly 51 — it’s hormone replacement in the literal sense, restoring what the ovaries would have been producing anyway. The bone protection benefit in premature menopause is substantial and pretty much unambiguous.
Practical Testing and Monitoring for Bone Health
Proactive monitoring generates the data you need to intervene before fracture, and to know whether interventions are actually working. For women committed to bone health for the long haul, here’s the monitoring framework that provides that feedback loop.
DEXA scanning is the standard density assessment. At natural menopause for all women — regardless of other risk factors, to establish a baseline at this clinically critical transition — and earlier if risk factors are present. If osteoporosis treatment starts, repeat DEXA at 2 years to assess response. If on pharmacological treatment for 5 years, repeat DEXA to inform the drug holiday decision. Spine and hip are the sites that matter clinically for fracture prediction.
Bone turnover markers — serum CTX (a resorption marker) and serum P1NP (a formation marker) — give you dynamic information about remodeling that DEXA can’t. They’re useful for confirming whether bisphosphonate treatment is adequately suppressing resorption (CTX should decline with treatment), distinguishing high-turnover from low-turnover bone loss in treatment planning, and monitoring response faster than waiting 2 years for a repeat DEXA. These are available at major reference labs but aren’t routinely ordered — you’ll need to specifically request them from a bone-aware clinician or endocrinologist.
The FRAX tool, available free online, calculates 10-year fracture probability from clinical risk factors — age, sex, weight, prior fracture, family history, glucocorticoid use, and optionally, femoral neck T-score. It’s what actually drives treatment decisions — a 10-year major osteoporotic fracture risk above 20% is a standard treatment threshold in US guidelines. Running your own FRAX gives you a concrete risk number to bring to your clinician instead of leaning entirely on the osteopenia/osteoporosis label.
The clinical takeaway on bone health in women is that it’s a decades-long project requiring consistent attention at multiple life stages: maximizing peak bone mass through exercise and nutrition in youth, maintaining density through the premenopausal years with continued resistance training, managing the critical menopausal transition with appropriate hormonal and non-hormonal strategies, and optimizing the late-life bone-maintenance environment with continued exercise, nutrition, fall prevention, and pharmacological support when indicated. It’s not one decision. It’s a continuing series of decisions across a lifetime, each building on the last. The women who handle it best are the ones who understand the biology, not just the instructions.
Medications That Steal Bone: What to Know
A lot of commonly prescribed medications carry bone loss as a significant side effect — and that complication gets underemphasized at prescribing time and undermanaged in patients who’ve been taking these drugs for years. Women on them need proactive bone monitoring and often concurrent bone-protective intervention.
Glucocorticoids — prednisone, prednisolone, dexamethasone, cortisone, and high-dose inhaled corticosteroids including fluticasone above 1mg/day — are the most potent drug class for bone loss there is. The mechanism runs on multiple tracks: direct suppression of osteoblast activity and lifespan, decreased calcium absorption, increased renal calcium excretion, suppression of sex hormone production, and reduced muscle mass, which itself cuts mechanical loading of the skeleton. Loss begins within the first weeks of therapy and is fastest in the first 6-12 months. Any woman starting chronic glucocorticoid therapy should get a DEXA scan within the first year, and bone-protective medication should be strongly considered from the start if bone density is already below normal or treatment is expected to run more than 3 months.
Proton pump inhibitors — omeprazole, pantoprazole, lansoprazole, among the most widely prescribed drugs in existence — reduce gastric acid, which calcium carbonate needs for dissolution and absorption. Long-term PPI use, over a year, is associated with a 15-35% increase in fracture risk across multiple population studies. Calcium citrate, which doesn’t require acid for absorption, is the right calcium form for PPI users. Periodically reassessing whether the PPI is still needed, and stepping down to the lowest effective dose or an H2 blocker when clinically appropriate, reduces this risk.
Aromatase inhibitors — anastrozole, letrozole, exemestane, used for hormone receptor-positive breast cancer — suppress estrogen production to near zero in postmenopausal women, causing accelerated bone loss comparable to the early-menopause window. Every woman starting aromatase inhibitor therapy should get a baseline DEXA, vitamin D optimization, calcium adequacy, and often a co-prescribed bisphosphonate. Bone loss from aromatase inhibitor therapy is one of the most significant long-term side effects of breast cancer treatment, and oncology teams need to manage it proactively rather than waiting for fractures.
Antidepressants — particularly SSRIs and SNRIs — have emerging evidence for a modest association with bone loss, through direct effects on serotonin receptors expressed in osteoblasts and osteoclasts, since bone cells carry serotonin receptors and serotonin modulates remodeling. The effect size is modest but measurable in long-term users. This isn’t an argument against treating depression — undertreated depression has its own metabolic and behavioral consequences for bone health. It’s an argument for awareness in women on long-term antidepressant therapy, making sure concurrent bone health optimization is actually part of their care.
Carol’s message to women reading her story would be this: don’t wait for a DEXA scan at 57 to find out what you’ve already lost. The decisions that mattered most happened 20-30 years before that scan. The opportunity cost of those decades — adequate calcium, consistent resistance training, optimal vitamin D — isn’t just statistical. It’s the difference between a fracture at 75 that ends independence and a hip that holds together for a life fully lived. The biology is learnable. The interventions are available. The only thing that fails most women here is a system that doesn’t tell them early enough to act on it. Consider yourself told. The biology of bone spans decades. Invest early.
The Practical Framework: Applying Health Post 615 In Real Life
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map